FIELD: medicine.SUBSTANCE: invention relates to medicine and deals with application of erythropoietic molecule for obtaining medication for treatment of neurodegenerative disorders of brain and spinal cord by introduction of efficient amount of medication into the bloodstream of patient requiring such treatment, in which erythropoietic molecule includes part of erythropoietin molecule, which has at least one free amino group, selected from group, including human erythropoietin and its analogues, which have human erythropoietin sequence, modified by addition of 1-6 sites of glycosylation or rearrangement of at least one site of glycosylation; said part of erythropoietin molecule is covalently bound with 'n' groups of polyethylene glycol of formula -CO-(CH)-(OCHCH)-OR with -CO of each polyethylene group, forming amide bond with one of said amino groups.EFFECT: invention ensures penetration of erythropoietic molecule through the barrier between blood and brain, good period of half-life, which makes it possible to introduce molecule in lower initial dose.19 cl, 3 ex, 3 dwg, 1 tbl
TREATMENT OF NEURODEGENERATIVE DISORDERS